China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South Korea’s ATGC, granting Huadong exclusive global rights (excluding India) to ATGC’s botulinum toxin A injection, ATGC-110. The agreement also provides a non-exclusive license for South Korea, encompassing clinical development, regulatory filing, and commercialization rights across all medical aesthetic and therapeutic indications.
Financial Terms and Milestone Payments
Under the terms of the agreement, Huadong will pay ATGC an upfront fee of USD 13 million. Additionally, Huadong is committed to up to USD 17 million in milestone payments tied to clinical development and regulatory filings. This partnership positions Huadong to enhance its portfolio in the rapidly growing aesthetic medicine market.
Innovative Features of ATGC-110
ATGC-110 is an investigational neuromodulator featuring a 150kDa type A botulinum toxin as its active ingredient. Designed to treat moderate to severe brow lines in adult patients, ATGC-110 stands out as a botulinum toxin free of complex protein components. This unique formulation aims to reduce drug resistance by eliminating non-toxic proteins that can lead to resistance, offering a safer option for repeated and high-dose treatments.-Fineline Info & Tech
